Lineage Cell Therapeutics, Inc. Prepaid Expense and Other Assets, Current
Lineage Cell Therapeutics, Inc. (LCTX) had Prepaid Expense and Other Assets, Current of $1.35 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $1.35M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $1.98M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $2.48M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $1.65M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.35M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $2.48M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.65M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.30M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $1.87M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $2.55M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $1.28M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $1.66M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.02M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.20M 10-K · filed 2025-03-10 | |
| 2023-09-30 | $1.72M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $2.12M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.64M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.83M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $1.72M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $1.29M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $1.41M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $2.35M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $3.16M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $2.50M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $2.15M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $2.43M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $1.41M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $1.38M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $2.23M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.86M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $2.34M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $2.10M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $2.16M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $1.90M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $1.76M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.57M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $1.75M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.40M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $1.35M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $1.59M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $1.51M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $1.78M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $2.08M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $1.79M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $2.88M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $2.61M 10-K · filed 2017-03-16 | $2.61M 10-K · filed 2016-03-15 |
| 2015-09-30 | $1.75M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.49M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.27M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $1.23M 10-K · filed 2016-03-15 | $1.23M 10-K · filed 2015-03-11 |
| 2014-09-30 | $1.26M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $1.48M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.55M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $1.16M 10-K · filed 2015-03-11 | $2.28M 10-K · filed 2014-03-17 |
| 2013-09-30 | $1.90M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $3.76M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $3.02M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $2.77M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $1.86M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $1.89M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $2.10M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $2.69M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $2.26M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $1.98M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $2.20M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |